Vertex Pharmaceuticals, Inc. (VRTX)

Revenue & Earnings

Balance Sheet

Share Statistics

Compare to

Market

Industry

Market Cap The market value of the company. It's calculated by multiplying the share price by the number of outstanding shares.	$91.4 Billion
Enterprise Value A measure of a company's total value. This includes market cap, cash, and debt.	$79.9 Billion
Dividend Yield Yearly payout to shareholders per share. The percentage indicates the payout in relation to the share price.	$0.00 (0.0%)
1 Year Return Profit or loss of share price change plus dividend yield.	+12.1%
52-Week High Highest share price in the last 52 weeks.	$387.42
52-Week Low Lowest share price in the last 52 weeks.	$282.21
Beta Beta indicates the volatility of a stock compared to the market. Higher beta means more volatile and thus potentially higher risk and return.	0.0
Outstanding Shares The number of shares the company has issued and are held by stockholders.	258 Million
Avg 30 Day Volume The number of shares traded in the last 30 days.	1.56 Million

Valuation

Compare to

Market

Industry

P/E Ratio Ratio between share price and earnings per share. A low ratio could indicate that the stock is undervalued or investors aren't expecting high growth. A high ratio could indicate that the stock is overvalued or investors are expecting high growth.	26.35
PEG The ratio between the P/E ratio and the growth rate of the company's earnings per share in the last twelve months. A lower PEG could mean that a stock is undervalued.	233.96
Earnings per Share Earnings divided by outstanding shares. Higher EPS indicates greater value.	$13.32
Price to Sales Ratio Market cap divided by the revenue in the most recent year.	9.48
Price to Book Ratio Price to Book Ratio is the Market cap divided by the Book value of the company	5.48
Enterprise Value to Revenue Enterprise value divided by revenue	8.28
Enterprise Value to EBIT Enterprise Value divided by EBIT	18.11
Total Debt to Enterprise Value Total debt divided by enterprise value	0.0
Debt to Equity A higher ratio indicates a higher risk. However, the ratio is difficult to compare between industries where common amounts of debt vary.	0.02

Profitability

Compare to

Market

Industry

Revenue Revenue is the sum of all cash flow into the company.	$9.65 Billion
Gross Profit Gross profit is the profit after subtracting the costs of making and selling its products or the costs of providing its services. It indicates the efficiency of using their resources to produce goods or services.	$8.48 Billion
EBIT Earnings before tax and interest payments.	$4.41 Billion
Net Income Net Income is the profit after all expenses have been deducted from the total revenue.	$3.47 Billion
Profit Margin Net income divided by revenue of the last 4 quarters. It indicates the company's profitability.	35.94%
Quarterly Earnings Growth (YoY) The rate at which the company's net income has increased to the same quarter one year ago.	+11.3%
Return on Equity Equity divided by market cap.	21.01%
Return on Assets Indicates a company's profitability in relation to its total assets.	15.97%
Return on Invested Capital Return on invested capital (ROIC) is net income after dividends divided by the sum of debt and equity. It shows how effective a company is at turning capital invested by shareholders and other debtholders into profits.	24.34%

Insider trades

Q1 2023 Q2 2023 Q3 2023 Q4 2023

About Vertex Pharmaceuticals, Inc.

CEO: Jeffrey Leiden

Industry: Pharmaceutical Preparation Manufacturing

Similar stocks

Gilead Sciences, Inc.

Abbvie Inc

Merck & Co Inc

Johnson & Johnson

Enzon Pharmaceuticals Inc

Enanta Pharmaceuticals Inc

News

Pro Research: Wall Street dives into Vertex Pharmaceuticals'' prospects

https://www.investing.com/news/stock-market-news/pro-research-wall-street-dives-into-vertex-pharmaceuticals-prospects-93CH-3249237

Investing.com, about 14 hours ago

3 Biotech Stocks That Could Be Multibaggers in the Making

In the dynamic realm of modern medicine, biotech stocks have effectively emerged at the forefront of a transformation. These innovative players are steering ...

InvestorPlace, 5 days ago

Health Canada grants expanded approval of Vertex CF drug in infants

Health Canada has granted expanded market authorization for Vertex Pharmaceuticals'' (VRTX) drug Kaydeco for the treatment of cystic fibrosis in children age...

Seeking Alpha, 6 days ago